The SUGAR Study; SBRT and Relugolix) for Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical trial is to measure the toxicity and effectiveness of the following treatments for cFIR/cgUIR prostate cancer patients. Stereotactic body radiotherapy (SBRT) alone or Stereotactic body radiotherapy (SBRT) combined with Ultrashort GNRH Antagonist called Relugolix (an oral drug). Treatments will be randomly assigned to study patients. The main questions it aims to answer are the following: 1. Whether the proportion of men who undergo SUGAR have superior rate of attaining PSA nadir of \<= 0.2 compared to SBRT alone, and 2. Whether SUGAR is superior to historical rates of minimal clinically important decline (MCID) in sexual and hormonal function at 6 months for patients undergoing 6 months of androgen deprivation therapy (ADT) Men aged 18+ with cFIR/cgUIR will be enrolled. Specifically, patients must meet one of the following 2 criteria: 1) Gleason score must be Gleason 3+4 with a PSA \< 20 ng/mL, or 2) Gleason 6 (3+3) and PSA \> 10 ng/mL and \< 20 ng mL.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyzna w wieku 18 lat lub starszy (lub osoba transpłciowa urodzona z prostató, jeśli nie przyjmowała leczenia obniżającego testosteron)
- •Potwierdzony nowotwór złośliwy prostaty
- •Wynik biopsji: Gleason 3+4 z PSA < 20 ng/mL, lub Gleason 6 (3+3) z PSA > 10 ng/mL i < 20 ng/mL
- •Testosteron w krwi > 100 ng/dL
- •PSA w krwi > 0,2 ng/mL
- •Zdolność przyjmowania leków doustnie przez cały okres badania
- •Objętość prostaty ≤ 80 cc (zmierzona MRI lub ultrasound)
- •Gotowość do stosowania antykoncepcji przez cały czas leczenia i 4 miesiące po
✗ Disqualifies
- •Stosowanie leków wydłużających odstęp QT na EKG
- •Uczulenie na Relugolix
- •Poprzednie leczenie innych badań klinicznych w ostatnich 30 dniach
- •Historia zapalenia jelita grubego lub innych chorób zapalno-niezapalnych
- •Choroby tkanki łącznej (toczeń, skleroderma, zapalenie mięśni)
- •Wcześniejsze leczenie agonistami GNRH lub SBRT prostaty
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 21, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (4)
Yale Cancer Center
New Haven, United States
Dartmouth-Hitchcock Medical Center
Lebanon, United States
Memorial Sloan Kettering Cancer Center
New York, United States
University of Washington
Seattle, United States
Trial contact
Camalene Chrysostoum
Tara McPartland
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.